Authors
Latest:
Investing for Success: Finding the Right Launch BalanceChallenge assumptions and reset expectations when it comes to pre-launch SG&A investment to increase the odds of commercial success.
Latest:
A Case for Payer Engagement and Participation in Clinical ResearchCollaboration can make commercialization processes efficient and effective.
Latest:
The Teladoc-Livongo Merger: Life Science Manufacturers’ Darwinian MomentThe recent merger of Teledoc and Livongo into a $38 billion titan proves that the market sees opportunity in health tech. Could it be an inflection point in our race towards a digital-first care model, or is this an experiment ahead of its time?
Latest:
How Medical Affairs Can Contribute to Successful Drug LaunchFaster launch planning leads to greater access.
Latest:
Navigating the Payer-Health System Nexus: A Strategic Imperative for Biopharma Commercial SuccessThe traditional biopharma approach focused primarily on physician detailing and securing favorable payer contracts, has become inadequate in today’s market.
Latest:
China: The Giant Has AwokenWith a new Chinese pharma or biotech company listing on either the HKEX or STAR exchange in China almost every week, it is important consideration US pharma and biotech companies to have a focused China market strategy, writes Enoch Kariuki.
Latest:
The Consolidated Appropriations Act and PBM TransparencyNew federal law introduces significant changes in the design of pharmacy benefit plans with aims to level the playing field between PBMs and their employee healthcare benefit plan clients.
Latest:
Embracing the Hybrid Era: Leveraging Answer Engines and Generative AI to Improve the Patient and HCP ExperienceThrough the power of large language models and generative AI, pharma and biotech companies are transforming medical information delivery by offering direct, trustworthy, and accurate answers to patients and healthcare providers, significantly reducing time and frustration.
Latest:
Enhancing Supply Chain Resilience amid Complexity in Pharma and Medical DevicesThe growing complexity of supply chains necessitates the adoption of collaborative planning processes and capabilities such as S&OP and S&OE.
Latest:
The Cultural Deficit in the Pharma Industry in the Era of COVID-19Multicultural campaigns crafted for diverse populations are insufficiently funded and do not receive the same support as mainstream campaigns, writes Sheila Thorne. While there are plenty of people willing to partner with pharma on these campaigns, will the industry wake up to the changing world ahead?
Latest:
Measuring Pharma’s Trust PerformanceThe core building blocks of trust must be operationalized for pharma companies to strengthen their social contract, deliver business value, and improve patients’ quality of life.
Latest:
Advancing Healthcare Solutions: Harnessing Collaborative Business Models for OncologyUnique approaches are needed to bring solutions to fighting cancer and bacterial-resistant infections.
Latest:
Don’t Get Distracted By AI, Instead Focus on Intellectual PropertyArtificial intelligence is making it quicker to get drug candidates to the clinic, but it isn’t addressing the fundamental need to marry the right candidate and the right target to the right disease.
Latest:
How Life Sciences Can Move to Manufacturing 4.0 While Meeting Market DemandsHere are four ways life sciences organizations can quickly and cost-effectively achieve Manufacturing 4.0 benefits while still getting treatments to market.
Latest:
In DOJ Crosshairs: Rethinking Commission-Based Deals With Independent ContractorsPharma companies should review their commission-based compensation arrangements with independent contractors to address enforcement risk under the Anti-Kickback Statute, in light of recent Department of Justice enforcement.
Latest:
What Do Pharma Marketers Need to Know About Voice?Pharma marketers can use their "voice" to increase prominence in advertising.
Latest:
Why Pharma Must Invest in Key Account Management CapabilitiesThe emergence of organized customers demands investment in advanced solutions and next-generation key account management.
Latest:
Drug Manufacturers Take A Fresh Look as PAPs Continue to Hold SpotlightPatient Assistance Programs (PAPs) came out of the shadows in 2020 as several factors aligned that increased demand and awareness of these programs.
Latest:
Silver Linings of a Global Health Crisis: A New Path Forward for Pharma Media Professionalsat some point, we won’t be seeing wall-to-wall COVID coverage anymore, but stories about the fallout. How can pharmaceutical brands prepare for what’s next?
Latest:
Tapping Compliance Data to Drive SuccessHow pharma leaders can convert data collected for compliance purposes from a cost center into a critical success factor.
Latest:
The Future of Launch Excellence is Generative AIHow drugmakers can reap value from using generative AI in their market-entry strategies and decision-making, including mitigating launch challenges and enhancing the customer conversation.
Latest:
Gaining Payer Attention Through Digital InnovationIn this case study, learn how to increase payer engagement, drive awareness, monitor competition, and leverage insights to enhance strategic plans and launch success.
